# [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

> clinical trial · VERIFIED · 2026-07-06

Status: ACTIVE_NOT_RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Breast Cancer

- Company: Novartis Pharmaceuticals
- Sector: Breast Cancer
- Primary source: https://clinicaltrials.gov/study/NCT05870579

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.